SCHEMBL4487003

SCHEMBL4487003

COc1cc2c(Oc3ccc(NC(=O)NCCC(C)(C)C)c(Cl)c3)ccnc2cc1OCCN1CCN(C)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 0.57
FLT1 P17948 11/20 0.57
FLT4 P35916 11/20 0.57
PDGFRA P16234 3/20 0.53
KIT P10721 2/20 0.53
RIPK2 O43353 1/20 0.53
STK10 O94804 1/20 0.53
ABL1 P00519 1/20 0.53
LCK P06239 1/20 0.53
LYN P07948 1/20 0.53
RET P07949 1/20 0.53
MET P08581 1/20 0.53
PDGFRB P09619 1/20 0.53
BCR P11274 1/20 0.53
FGFR1 P11362 1/20 0.53
SRC P12931 1/20 0.53
MAPK3 P27361 1/20 0.53
HTR2A P28223 1/20 0.53
MAPK1 P28482 1/20 0.53
EPHA2 P29317 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4461260 0.97 KDR (0.58) KDRFLT1FLT4PDGFRAKIT
SCHEMBL4477592 0.96 KDR (0.61) KDRFLT1FLT4
SCHEMBL4475699 0.95 KDR (0.63) KDRFLT1FLT4
SCHEMBL4467632 0.94 KDR (0.62) KDRFLT1FLT4
SCHEMBL4468824 0.94 KDR (0.62) KDRFLT1FLT4
SCHEMBL4481083 0.94 KDR (0.62) KDRFLT1FLT4
SCHEMBL4468968 0.93 KDR (0.59) KDRFLT1FLT4PDGFRAKIT
SCHEMBL4489349 0.92 KDR (0.55) KDRFLT1FLT4PDGFRAKIT
SCHEMBL4475415 0.92 KDR (0.55) KDRFLT1FLT4PDGFRAKIT
SCHEMBL5208159 0.92 KDR (0.62) KDRFLT1FLT4PDGFRAKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 KDR 211/4885FLT1 115/4885FLT4 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.